A defining 2026 trend in the pharmaceutical industry is the rise of "isoform-selective" JAK inhibitors designed to minimize the side effects associated with earlier, broader versions of the drug. In 2026, the market is pivoting toward highly specific inhibitors—targeting JAK1, JAK2, JAK3, or TYK2 individually—to reduce the risk of serious adverse events like thrombosis and...
จองคิวบริการ
NR tours
Youplay
NR shop
NR jobs
facebook th
